AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06331091 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: Manual therapy is special techniques for soft tissues and joints applied by a physiotherapist.
Study NCT06331091 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Description: Home exercise are done at home without the supervision of a specialist. Manual therapy is special techniques for soft tissues and joints applied by a physiotherapist.~Neuromuscular electrical stimulation is the application of electrical current to the muscle through special electrodes in order to increase muscle strength.~Supervised exercise is done under the supervision of a physiotherapist.
Study NCT06331091 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised exercise
Description: Supervised exercise is done under the supervision of a physiotherapist.
Study NCT06170970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solriamfetol
Description: solriamfetol 75 mg daily for 3 days and will increase the dose to 150 mg daily starting on day 4 of the treatment period (total of four weeks)
Study NCT06170970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Four weeks of oral placebo
Study NCT04684927 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MID-C System -Minimal invasive deformity correction system for the treatment of AIS
Description: A 5 years follow-up will be performed for all patients who underwent AIS repair surgery using the MID-C System. The follow-up in order to assess safety and efficacy measurments. Eligible Patients will be followed and assessed at the following time points: Immediate Post-op up to 6 weeks, 6 months, 12 months, and then annually out to 5 years post-implantation.~During the study, the following rating scales and assessments will be conducted to assess the probable benefit and safety of the treatment: Physical exam,X-rays,Cobb angle measurements,Adverse Events (AEs) and Scoliosis research society (SRS-22) questionnaire: The questionnaire is commonly used to assess health related quality of life in children with AIS.
Study NCT06656156 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation technique
Description: Experimental group was given proprioceptive neuromuscular facilitation technique (PNF) along with conventional treatment.~PNF will be applied on iliopsoas and hamstring muscles, 3 repetitions/session with a break of 2 minutes/repetition (10 second isometric Contraction then 10 second stretch)~Treatment contains total 12 sessions (3 times/week for 4 consecutive weeks)
Study NCT06656156 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Conventional treatment contains tens and hotpack.~Tens Will be applied for 20 minutes and hotpack for 10 minutes~Total 12 sessions (3 times/week for 4 consecutive weeks)
Study NCT05439616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Oral Capsules or Oral Solution
Study NCT05439616 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsules or Oral Solution
Study NCT04704934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: 6.4 mg/kg IV infusion every 3 weeks on Day 1 of each 21-day cycle
Study NCT04704934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramucirumab
Description: 8 mg/kg IV infusion on Days 1 and 15 of a 28-day cycle
Study NCT04704934 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 80 mg/m\^2 IV infusion on Days 1, 8, and 15 of a 28-day cycle
Study NCT05564767 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: B. adolescentis Bif-038
Description: B. adolescentis Bif-038 (probiotic capsule) delivered orally once daily at a minimum of 5 billion CFU/day
Study NCT05564767 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lacticaseibacillus rhamnosus, LGG® and Bifidobacterium, BB-12®
Description: Lacticaseibacillus rhamnosus, LGG® and Bifidobacterium, BB-12® (probiotic capsule) delivered orally once daily at a minimum of 1 billion CFU/day
Study NCT05564767 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule delivered orally once daily
Study NCT05390216 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial capsule decortication
Description: The anterior wall of the capsule was removed during the operation.
Study NCT05857085 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide Pen Injector [Ozempic]
Description: GLP 1 agonist
Study NCT05857085 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 10 MG
Description: SGLT 2 inhibitor
Study NCT06249620 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inmunoferon
Description: The dosage regimen is two capsules (with the active ingredients) per day in a single dose.The study lasted 8 weeks, with 2 interventional visits at baseline and at 8 weeks. Blood samples are collected twice: once on day 0 of the study and again at the final visit.
Study NCT06249620 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The dosage regimen is two capsules (with inert ingredients) per day in a single dose.The study lasted 8 weeks, with 2 interventional visits at baseline and at 8 weeks. Blood samples are collected twice: once on day 0 of the study and again at the final visit.
Study NCT06413550 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Hibiscus Sabdariffa
Description: The fresh red Roselle plant was obtained; the red calyxes of Hibiscus Sabdariffa were separated from the plant and dried for a week at 25°C. The dried calyxes were ground to powder, kept in a sealed container, and stored in a refrigerator (4°C) until used. Aqueous Roselle calyx extract was prepared by adding 10 gm of the previously prepared powder to 100 ml of boiling water and then heated on a hot stirrer plate for 30 min. To remove the remnants, the mixture was filtered via Whatman No 1 filter paper (Whatman products, Springfield Paper Mill, Maidstone, UK). The water content of the filtered solution was evaporated using an air recirculation oven and then kept at 4°C in the dark until used to determine antibacterial effectiveness \[20\].
Study NCT06413550 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hibiscus Sabdariffa
Description: The fresh red Roselle plant was obtained; the red calyxes of Hibiscus Sabdariffa were separated from the plant and dried for a week at 25°C. The dried calyxes were ground to powder, kept in a sealed container, and stored in a refrigerator (4°C) until used. Aqueous Roselle calyx extract was prepared by adding 10 gm of the previously prepared powder to 100 ml of boiling water and then heated on a hot stirrer plate for 30 min. To remove the remnants, the mixture was filtered via Whatman No 1 filter paper (Whatman products, Springfield Paper Mill, Maidstone, UK). The water content of the filtered solution was evaporated using an air recirculation oven and then kept at 4°C in the dark until used to determine antibacterial effectiveness \[20\].
Study NCT04847700 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical treatment
Description: Endoscopic retrosigmoid minimally invasive vestibular neurectomy
Study NCT05294874 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: gait training
Description: walking forward, sideway and backward walking on balance board
Study NCT05294874 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gait training
Description: walking forward, sideway and backward walking on balance board
Study NCT04847700 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical treatment
Description: Endoscopic tenotomy of middle ear muscles
Study NCT06208488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefurulimab PFS-SD
Description: Participants will receive a single 600 mg dose of Gefurulimab PFS-SD subcutaneously (SC) on Day 1.
Study NCT06208488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefurulimab AI
Description: Participants will receive a single 600 mg dose of Gefurulimab AI subcutaneously (SC) on Day 1.
Study NCT06339840 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diet group
Description: During the initial 8-week weight loss phase, participants will adopt a low-carbohydrate dietary pattern (with carbohydrate energy ratio of 20-30%, protein energy ratio of 30-40%, and fat energy ratio of 40-45%), with a caloric intake approximately 75% of their usual daily intake, but not less than 1200 kcal. Throughout the intervention period, participants will receive a daily nutritionally balanced meal replacement for 8 weeks to substitute for staple foods and control carbohydrate intake. Nutritionists will reinforce interventions by setting health goals, providing health education, implementing dietary and exercise interventions, and monitoring through a combined approach using a mobile platform. During the subsequent 4-week transition phase, participants' diets will gradually transition to a balanced dietary pattern (with carbohydrate energy ratio of 45-60%, protein energy ratio of 20-30%, and fat energy ratio of 20-25%) under the guidance of nutritionists.
Study NCT06339840 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Health Education Group
Description: Upon enrollment, nutritionists will provide lifestyle guidance to patients, including personalized adjustments such as limiting total energy intake to \<1600 kcal/day, adjusting macronutrient distribution to 45-55% for carbohydrates, 20-30% for fats, and 20-30% for protein. Participants are advised to accumulate at least 150 minutes of moderate-intensity aerobic exercise per week (achieving 50%-70% of maximum heart rate). At enrollment, nutritionists will educate participants on healthy lifestyle principles, train them on nutritional intervention tools, and assist in food selection for weight management planning. Throughout the intervention, nutritionists will conduct follow-ups with patients via phone or mobile platforms to monitor weekly dietary and exercise habits, weight changes, and address any participant concerns promptly.
Study NCT06490861 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paragit
Description: Sleeve to quantify symptoms
Study NCT04646148 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yoga classes
Description: All participants are invited to attend weekly yoga classes.
Study NCT05349955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive guideline algorithm implementation
Description: Diabetes guideline pharmacological algorithm will be implemented by primary care physicians in community. In brief, SGLT2i or GLP-1RA will be recommended to control blood glucose in priority when subjects at very high/high CV risk and meet the target HbA1C\<7%, control blood pressure \<130/80mmHg， LDL-c\<1.8mmol/L at very high CV risk patients or \<2.6mmol/L at high CV risk patients, and antiplatelet as secondary prevention of ASCVD.
Study NCT05349955 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional guideline algorithm implementation
Description: The guideline intervention is based the guidance which the local physicians followed through self learning and education. The management of diabetes paitients will be decided by local physicians.
Study NCT05028803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium phenylbutyrate
Description: same as arm/group
Study NCT05802030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric training
Description: Plyometric training can be described as a type of exercise that involves a rapid and forceful movement that consists of an eccentric contraction, followed by an immediate and explosive concentric contraction. Upper and lower limb plyometrics are exercises that enable an upper and lower body muscle group to react quickly to produce maximal strength
Study NCT05802030 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine training
Description: Regular tennis training, including normal fitness training, and injury prevention drills
Study NCT05356767 — intervention group
Intervention type: PROCEDURE
Intervention: Pharmacomechanical thrombolysis
Description: Pharmacomechanical thrombolysis
Study NCT04884568 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exufiber
Description: Wound dressed with Exufiber for up to 21 days.
Study NCT06109298 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold spray
Description: Cold spray was applied for 5 seconds at a distance of 15 cm to an area of approximately 5 cm2 at the site of the procedu
Study NCT04665557 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dove Confident Me Indonesia Single Session
Description: Dove Confident Me Indonesia Single Session is an adaptation of Dove Confident Me Global Single Session, designed to be facilitated by schoolteachers or school counsellors. Dove Confident Me Indonesia includes four interactive activities (to be delivered in a single 90-minute session) as well as a homework challenge and commitment pledge. The programme incorporates three primary techniques to improve Indonesian adolescents' body confidence and self-esteem: (1) psychoeducation, (2) media literacy, and (3) cognitive dissonance as well as two secondary techniques: (4) self-affirmation and (5) cognitive reframing. As the curriculum was adapted to be delivered in Indonesian schools with limited resources, videos or PowerPoint presentations are not included. Instead, a detailed teacher guide and student worksheets are provided.~Due to COVID-19, the intervention will be delivered online via video conferencing platform.
Study NCT05704114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazarotene 0.045% Lotion
Description: Daily topical use of tazarotene for 16 weeks.
Study NCT05354960 — intervention group
Intervention type: OTHER
Intervention: Questionnaire validation
Description: Validation and cultural adaption of the German version of the LIMB-Q
Study NCT05258461 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: use of a smartphone app for adverse event management
Description: At their enrollment, patients will receive detailed introduction and adequate assistance on the use of the smartphone app. The smartphone app will offer proper advice for adverse event management based on calculated results by artificial intelligence on the innovative app, which was developed by YL et al. It was specifically intended for risk prediction, early prevention, as well as management of symptoms and concerns during adjuvant chemotherapy in the treatment of breast cancer. The app consisted of 4 modules: (1) Module 1: clinical data collection. (2) Module 2: risk evaluation for 12 common adverse events during breast cancer chemotherapy. (3) Module 3: personalized prophylaxis based on predicted risks of adverse events. (4) Module 4: Q\&A platform.
Study NCT05258461 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional adverse event management
Description: Chemotherapy-related adverse events in the control group will be managed with symptomatic treatment, dietary and lifestyle prescription according to the doctors' clinical experience. For example, colony-stimulating factors and antibiotics may be used for febrile neutropenia, loperamide (or diphenoxylate plus atropine) as prophylaxis for diarrhea, together with eating low-lactose and low-fat frequent small meals. 5-hydroxytryptamine 3 receptor antagonist, neurokinin 1 receptor antagonist, and/or dexamethasone would be prescribed for patients at high risks of vomiting.
Study NCT06109298 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Refrigerated gel ice
Description: Refrigerated gel ice was applied for 5 minutes at 2 cm above the area to be treated.
Study NCT05258461 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional adverse event management
Description: Chemotherapy-related adverse events in the control group will be managed with symptomatic treatment, dietary and lifestyle prescription according to the doctors' clinical experience. For example, colony-stimulating factors and antibiotics may be used for febrile neutropenia, loperamide (or diphenoxylate plus atropine) as prophylaxis for diarrhea, together with eating low-lactose and low-fat frequent small meals. 5-hydroxytryptamine 3 receptor antagonist, neurokinin 1 receptor antagonist, and/or dexamethasone would be prescribed for patients at high risks of vomiting.
Study NCT05195528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Orally via capsule
Study NCT05946460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aumolertinib
Description: Aumolertinib treatment (110mg, p.o., QD) for 8 weeks
Study NCT05195528 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally via capsule
Study NCT06421870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10mg Tab
Description: Patients will be given dapagliflozin 10 mg once daily
Study NCT06421870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentoxifylline 400 MG
Description: Patients will be given pentoxyifylline 400 mg twice daily
Study NCT05621226 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COVID Booster text messages
Description: Participants will receive text messages per descriptions listed in the arms.
Study NCT04755829 — intervention group
Intervention type: DEVICE
Intervention: BreathX test for breath VOCs
Description: Breath samples are collected into an ultra-clean bag and breath VOCs are analyzed with GC-SAW.
Study NCT05904392 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Music played prior to injection
Study NCT05855733 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: radiofrequency treatment
Description: patient undergoing radiofrequency using the Fistura procedure for treatment of a infected pilonidal sinus
Study NCT06359184 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: yoga
Description: 1 hour yoga practice 2 days a week for 8 weeks
Study NCT06359184 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: no intervention for 8 weeks
Study NCT05222321 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensory-Play Based (SenPlay) Intervention
Description: SenPlay is a sensory-play based intervention that includes deep tactile pressure, vestibular and proprioceptive input as a therapeutic medium to facilitate optimal arousal through sensory-play based activities such as pushing, pulling, climbing, jumping, crashing, and swinging. These activities are designed to facilitate changes in the child's arousal through providing sensory input to ensure the child is reaching a threshold of moderate to vigorous physical activity. Completed at three time points, once weekly for three weeks.
Study NCT05222321 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Spontaneous, Free Play
Description: Participant engages in spontaneous, free play with the investigator supervising only for safety within the sensorimotor gym for 15 minutes. Completed at three time points, once weekly for three weeks.
Study NCT05679427 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiosurgery and stereotactic ablative radiotherapy with simultaneous integrated boost, respectively
Description: Two protocols of stereotactic ablative radiotherapy, in one vs five fractions ( the later with SIB) are compared
Study NCT05578547 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: combined Kendell and McKenzie cervical posture correction exercises, ultrasound, hot packs, cervical extensors stretching and strengthening exercise.
Description: • The combined exercise will be done as follow:~1) slowly pull the subject's neck to the head, thereby attaching the chin to the neck.~(2) the subject's eyes should be looking directly forward. (3) hold both hands on the back of the subject's head. (4) ask the subject to push his/her head backwards against the hands. (5) ask for the hands to be spread as wide as possible in order to stretch the pectoralis major.~Therapeutic ultrasound:~Moist heat packs:~Stretching Exercises:~Posture correction exercises training for forward head posture includes stretching of tight muscles such as Pectoralis major, levator scapulae, upper trapezius, suboccipital muscles, sternocleidomastoid Stretching exercises of pectoralis major, levator scapulae, upper fibres of trapezius, suboccipital muscles, sternocleidomastoid Strengthening Exercises Chin Tucks exercise Neck isometric exercises
Study NCT05578547 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ultrasound, hot packs, cervical extensors stretching and strengthening exercise.
Description: Therapeutic ultrasound:~Moist heat packs:~Stretching Exercises:~Posture correction exercises training for forward head posture includes stretching of tight muscles such as Pectoralis major, levator scapulae, upper trapezius, suboccipital muscles, sternocleidomastoid Stretching exercises of pectoralis major, levator scapulae, upper fibres of trapezius, suboccipital muscles, sternocleidomastoid Strengthening Exercises Chin Tucks exercise Neck isometric exercises
Study NCT05546762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-iodine solution
Description: Pleural irrigation with 2% povidone iodine
Study NCT05546762 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Pleural irrigation with normal saline
Study NCT04847388 — intervention group
Intervention type: DRUG
Intervention: Substance like alcohol, marijuana, etc.
Description: Cohort study
Study NCT05215184 — intervention group
Intervention type: DEVICE
Intervention: Zeto WR19 EEG Recording
Description: 15 minutes of EEG recording to be obtained from eligible participants
Study NCT04399382 — intervention group
Intervention type: DRUG
Intervention: Biologics
Description: The exposure of interest in this observational study is the biological therapy of Tumor Necrosis Factor (TNF) inhibitor, specifically etanercept biosmilar/ infliximab/ adalimumab/ golimumab.